Statements (128)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:PD-L1
gptkb:nivolumab gptkb:Keytruda |
| gptkbp:activities |
PD-1 inhibitor
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA gptkb:EMA |
| gptkbp:brand |
gptkb:Keytruda
|
| gptkbp:clinical_trial |
gptkb:KEYNOTE-001
gptkb:KEYNOTE-002 gptkb:KEYNOTE-006 gptkb:KEYNOTE-024 gptkb:KEYNOTE-189 gptkb:KEYNOTE-407 gptkb:KEYNOTE-716 gptkb:KEYNOTE-775 gptkb:vaccine Phase 1 combination therapy oncology Phase 2 Phase 3 first-line therapy second-line therapy KEYNOTE-010 |
| gptkbp:contraindication |
autoimmune diseases
hypersensitivity to pembrolizumab |
| gptkbp:date |
2015-09-17
|
| gptkbp:discovered_by |
gptkb:Merck_&_Co.
|
| gptkbp:dosage_form |
gptkb:software_framework
solution for infusion |
| gptkbp:effective_date |
gptkb:2014
|
| gptkbp:healthcare |
2014-09-04
|
| https://www.w3.org/2000/01/rdf-schema#label |
pembrolizumab
|
| gptkbp:indication |
metastatic cancer
advanced cancer treatment for gastric or gastroesophageal junction adenocarcinoma treatment for recurrent or metastatic head and neck squamous cell carcinoma treatment for primary mediastinal large B-cell lymphoma first-line treatment for metastatic non-small cell lung cancer treatment for advanced squamous cell carcinoma of the skin adjuvant treatment for melanoma first-line treatment for metastatic melanoma recurrent cancer treatment for Merkel cell carcinoma treatment for advanced biliary tract cancer treatment for advanced colorectal cancer treatment for advanced endometrial cancer treatment for advanced melanoma with BRAF mutation treatment for advanced melanoma with NRAS mutation treatment for advanced neuroendocrine tumors treatment for advanced ovarian cancer treatment for advanced pancreatic cancer treatment for advanced prostate cancer treatment for advanced renal cell carcinoma treatment for advanced soft tissue sarcoma treatment for advanced thymic carcinoma treatment for advanced thyroid cancer treatment for classical Hodgkin lymphoma treatment for esophageal cancer treatment for hepatocellular carcinoma treatment for recurrent cervical cancer treatment for small cell lung cancer treatment for triple-negative breast cancer treatment for locally advanced or metastatic urothelial carcinoma treatment for advanced melanoma with high PD-L1 expression |
| gptkbp:ingredients |
C646 H1008 N178 O198 S4
|
| gptkbp:invention |
2028
patented |
| gptkbp:is_used_for |
treatment of melanoma
treatment of Hodgkin lymphoma treatment of bladder cancer treatment of non-small cell lung cancer treatment of head and neck squamous cell carcinoma treatment of gastric cancer treatment of head and neck cancer treatment of cervical cancer |
| gptkbp:license |
BLA 125514
|
| gptkbp:manager |
IV
intravenous |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe gptkb:Keytruda |
| gptkbp:name |
Essential Medicines
|
| gptkbp:regulatory_compliance |
approved
|
| gptkbp:related_to |
T-cell activation
tumor microenvironment cancer immunotherapy immune checkpoint inhibitors |
| gptkbp:research_areas |
gptkb:healthcare_organization
oncology immuno-oncology biologics pharmaceutical development |
| gptkbp:safety_features |
infusion-related reactions
immune-mediated adverse reactions potential for fetal harm |
| gptkbp:side_effect |
gptkb:fandom
gptkb:Company fatigue nausea hepatitis diarrhea rash skin reactions thrombocytopenia neuropathy pneumonitis colitis endocrinopathies thyroid dysfunction nephritis thyroiditis immune-mediated reactions pruritus myocarditis hypophysitis |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:targets |
gptkb:PD-1
|
| gptkbp:treatment |
gptkb:vaccine
checkpoint inhibitor |
| gptkbp:weight |
146 k Da
|